Fortress Biotech Inc (FBIOP) ニュース

Fortress Biotech to Participate in October 2024 Investor Conferences

MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements

MIAMI, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an...

Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference

MIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027

MIAMI, July 25, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”, or the...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

MIAMI, July 05, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO; FBIOP) (“Fortress”), an...